





Utilizing C. elegans to model tauopathy 
Presented by Cheong Maria Yu  
In partial fulfillment of the requirements for graduation with the Dean’s Scholars 












____________________________    ____________________ 
Jonathan Pierce-Shimomura, Ph.D.    Date 
Supervising Professor 
 
____________________________    ____________________ 
Ruth Buskirk, Ph.D.      Date 




Utilizing C. elegans to model tauopathy 
Presented by Cheong M Yu in partial fulfillment of the requirements for graduation 
with the Dean’s Scholars Honors Degree in Biology 
Supervised by Jonathan T. Pierce-Shimomura, Ph.D. 
 
Abstract 
Many neurodegenerative diseases are characterized by abnormal accumulation of proteins, 
including tauopathies such as Alzheimer’s disease (AD). AD is the most common form of 
dementia that is characterized by cognitive losses and neurodegeneration. Due to the presence of 
genes homologous to human genes known to be involved in AD development, the nematode 
Caenorhabditis elegans can be used to model neurodegenerative diseases such as AD. Here I 
contribute to the available nematode models by creating a new multi-copy overexpression tau 
model, generating the tools needed to create a single-copy overexpression tau model. I made and 
characterized a transgenic model expressing an extra-chromosomal array of a mutant form of tau 
(tau-P301L) driven by the promoter for the worm homolog of tau. Like a previous tau 
overexpression strain, this strain demonstrated impaired locomotion and decreased egg-laying 
relative to wild-type controls. However, the current model shows an adult-onset rather than 
larval-onset of behavioral impairments. A single-copy integration of the tau mutant, for which I 
prepared the constructs, will help to determine if the later onset in the current model is dose or 
location sensitive. Adult onset of impairments is an improvement over earlier onset in that it is 
easier to explore neurodegeneration outside of the context of development.  
 
1. Introduction 
1.1 Age-related neurodegenerative 
disease: An overview 
Several neurodegenerative diseases have 
been associated with abnormal aggregation 
of proteins, including Parkinson’s disease 
and Alzheimer’s disease (AD) [1, 2]. The 
most common form of dementia [3, 4], 
Alzheimer’s disease (AD) remains an 
unsolved mystery. With the expanding size 
of the elderly population due to prolonged 
lifetimes and the aging baby-boomer 
generation, the prevalence of AD is 
predicted to increase rapidly. AD patients 
suffer from gradual cognitive decline, 
including memory and language deficits. 
AD is characterized by two main hallmarks: 
Aβ plaques, formed from cleavage products 
of amyloid precursor protein (APP), and 
neurofibrillary tangles (NFTs), composed of 
hyperphosphorylated tau protein [3, 4]. 
However, the roles of Aβ plaques and NFTs 
in the development of AD are not yet clear. 
 
Figure 1. Use of fluorescent reporters to view neurons and APP and apl-1 accumulation via confocal 
microscopy in C. elegans (image from [13] Crisp et al., 2012). 
1.2 Tau pathology 
Several neurodegenerative diseases, 
collectively called “tauopathies,” have been 
linked to abnormalities in tau, a 
microtubule-associated protein involved in 
stabilizing the microtubules within a neuron 
[5, 6], including frontotemporal dementia 
with Parkinsonism [7] and Alzheimer’s 
disease [1, 2]. Although the microtubule 
network appears to be intact even with 
abnormal tau [6, 8], excess levels of tau 
appear to negatively affect functions 
associated with the neuron’s microtubule 
structure, such as vesicular transport, 
including transport of APP [8], which offers 
a possible relationship between tau and APP 
pathology in Alzheimer’s disease. 
Furthermore, mutations in tau have been 
identified that result in deposits of tau often 
characterized by rope-like or twisted 
filaments, and the associated dementia may 
be linked to hyperphosphorylation of the 
mutant tau [9].  
1.3 Caenorhabditis elegans as a model for 
tauopathy 
With the incidence of AD predicted to 
increase rapidly [10], it is necessary to find 
ways to explore age-related degeneration on 
a more efficient time-scale. Due to short 
developmental cycles, rapid aging studies 
are made possible using C. elegans. 
Additionally, AD is initially characterized 
by degeneration of cholinergic neurons. C. 
elegans have many cholinergic neurons 
involved in a wide variety of functions, 
including locomotion and egg-laying [11] 
and, due to transparent bodies, 
neurodegeneration and localization of 
proteins are observable through the use of 
fluorescent labeling (Figure 1). Furthermore, 
genes homologous to those associated with 
AD in humans, specifically APP and tau, are 
present in the worm [12], making this 
animal an appropriate model for exploring 
the role of these genes in AD etiology.  
 
 
1.4 Current C. elegans models of 
tauopathy 
Current nematode models of AD have been 
created via genetic manipulation by way of 
microinjection of desired genes. These genes 
may be expressed as part of an 
extrachromosomal array or they may be 
integrated into the genome. Current 
nematode models of tauopathy, which 
includes a number of dementias including 
AD, express a multi-copy integrated array of 
both wild-type and hyperphosphorylation-
prone mutant human tau driven by a pan-
neuronal promoter [7]. These models 
demonstrate a number of behavioral deficits, 
including uncoordinated locomotion and 
reduced egg-laying, and neurodegeneration 
[7]. However, since the observed phenotype 
of this model may be due to the 
overwhelming amount of tau expressed in 
the worm model, a model expressing a 
single copy of tau might lend more insight 
into tau-specific phenotypes. Making this 
model expressing tau driven by an 
endogenous promoter was attempted in this 
study using MosI-mediated single-copy 
insertion [14].  
 
C. elegans Strains 
Name Genotype Description Source 
N2 WT wild-type strain CGC 
EG4322 
(unc-119) 















Table 1. Four strains total were used in this project. Two strains were created for this project. 
2. Materials and Methods 
2.1 Strains and maintenance 
C. elegans strains were maintained on 
nematode growth media (NGM) agar plates 
seeded with OP-50 E. coli [15]. Plates were 
stored at room temperature (20°C). The 
following strains were used: wild-type N2, 
and EG4322. Two new strains were 
developed for this work: JPS519 and 
JPS520. See Table 1 for strain details.  
2.2 Creation of tau injection constructs 
for MosI-mediated single-copy insertion 
(MosSCI) 
2.2.1 Mutagenesis of WT human tau 
Vectors containing wild-type (WT) human 
tau (tau – 4 repeat (4R)) and a non-
aggregating form of human tau (tau-3-
repeat (3R)) were acquired from a connected 
lab (Eriksen lab). Using the Agilent 
mutagenesis kit and primers designed to 
introduce a point mutation into WT tau at 
amino acid 301 (P301L), a mutated version 
of the gene encoding human tau was 
formed: tau-P301L.  
2.2.2 Assembly and injection of tau 
constructs for MosSCI 
Each version of tau (tau-4R, tau-3R and tau-
P301L) was amplified through 
transformation of E. coli and Gateway 
overhangs were added to the gene using 
polymerase chain reaction (PCR). Using a 
BP reaction, each version of tau (tau-4R, 
tau-3R and tau-P301L) was integrated into 
Gateway entry vectors. The promoter for the 
worm homolog of tau (ptl-1p) was cloned 
from N2 whole worm lysis, PCR was used 
to add Gateway overhangs and the resulting 
product was inserted into a Gateway entry 
vector. A stock of Gateway entry vector 
containing unc-54 UTR (a frequently used 
untranslated region – UTR) was obtained. 
An LR reaction was performed to combine 
the three gene parts, creating the injection 
plasmids: ptl-1p::tau::unc-54. MosSCI tau 
injection mixtures were prepared as 
described in [14] Frøkjær-Jensen et al. 
(2008) and injected into EG4322 worms. 
2.3 Characterization Assays 
2.3.1 Head-bend assay 
Worms were staged by bleaching. Worms 
were moved (ten at a time) to an agar plate 
free of OP-50. The number of head-bends 
(complete left-right-left or right-left-right 
movement) made in 10 seconds while 
moving forward was counted for each 
worm. Each worm was removed after 
counting head-bends to avoid re-counting. 
Each set of ten worms was given ten 
minutes total for each worm to accomplish 
forward movement for 10 seconds. Worms 
that failed to move in the given ten minutes 
were given a count of “0” head bends. 
2.3.2 Liquid thrashing assay 
Worms were staged by bleaching. Worms 
were moved (ten at a time) into a 10ul 
puddle of M9 buffer (3g KH2PO4, 6g 
Na2HPO4, 5g NaCl, 1mL 1M MgSO4, H2O 
to 1 liter [15]) on an agar plate free of OP-
50. M9 was refreshed as needed. Worms 
were allowed to settle for 10-15 seconds. 
Thrashing movement was recorded for 1.5-2 
minutes using StreamPix 3 software (20-30 
fps). A segment of 10 seconds duration 
within the first minute of movement was 
chosen for analysis from each trial video. 
The percentage of worms able to accomplish 
at least one proper C-shaped bend during the 
10-second video segment was counted.  
 
Figure 3. Proper C-shaped bend made by C. 
elegans while swimming (image obtained from 
http://www.wormbook.org/chapters/www_beha
vior/behavior.html) 
2.3.3 Egg-laying assay 
Worms were staged by bleaching. Ten day 1 
adults were moved to a new NGM agar plate 
seeded with OP50 and left on the plate for a 
set number of hours (7 hours). Worms were 
removed from the plate after seven hours, 




C. elegans successfully incorporated ptl-
1::tau-P301L::unc54 UTR into an 
extrachromosomal array (JPS519 and 
JPS520). No other injections were 
successful and no injections yielded 
successful single-copy insertions. 
Transformants with potentially successful 
single copy insertions of tau-P301L and 
tau4R died without producing progeny. Due 
to the absence of other successful injections, 
JPS519 and JPS520 phenotypes were 
assessed using N2s as a control.  
3.1 Worms expressing extrachromosomal 
mutant tau-P301L demonstrate lower 
performance on behavioral assays 
As seen previously using a pan-neuronal 
promoter [7], transgenic worms expressing 
an extra-chromosomal array of tau-P301L 
driven by the promoter for the worm 
homolog (ptl-1) demonstrated reduced 
locomotive ability. Assessing locomotion on 
land, JPS519 and JPS520 showed less 
movement, characterized by a significantly 
decreased number of head-bends relative to 
N2 controls (Figure 4). (2-tailed t-test, 
p<0.001 for both JPS519 and JPS520).  
 
Figure 4. The number of head-bends accomplished (within 10-seconds of forward movement on an un-







Figure 5. The percentage of worms able to make a proper C-shaped bend while swimming was 
significantly lower in strains expressing extra-chromosomal tau-P301L. JPS519 and JPS520 data 
was compared to same-day N2s for each situation. (***p-value=<0.0001) 
Locomotive deficits were better observed in 
liquid thrashing assays, where tau-P301L-
expressing worms performed significantly 
worse than N2s (using Fisher’s exact test 
and comparing Tg data to same-day N2s, all 
p-values <0.0001). A significantly smaller 
percentage of worms were able to complete 
a C-shaped bend within a 10-second period 
in the strains expressing extra-chromosomal 
mutant tau-P301L (Figure 5). Though this 
effect seemed to have a slight tendency to 
worsen with age, this did not appear to be 
substantial. 
Transgenic worms were also observed to 
tend to lay fewer eggs. Although only three 
trials of the egg-laying assays were 
accomplished, strains expressing extra-
chromosomal tau-P301L (JPS519 and 
JPS520) appeared to lay fewer eggs than 
wild-type N2s (2-tailed t-test comparing Tg 
strains to N2 –JPS519: p=0.12; JPS520: 
p=0.053; Figure 6). However, there was not 












Figure 6. Tg strains expressing extra-chromosomal tau-P301L laid fewer eggs on a seeded NGM agar 
plate than wild-type N2 controls after a period of 7 hours.  
Although time did not allow for more 
specific assessments, general observations 
regarding the phenotype were also made. 
The head-bend and liquid-thrashing assays 
demonstrated impaired movement, and in 
conducting these assays, there appeared to 
be an amount of tail-dragging among 
transgenic worms that increased with age. 
Additionally, although no direct assessment 
of life-span was made, it was noted that in 
spite of moving similar numbers of worms 
from each strain (N2, JPS519 and JPS520) 
onto new plates for day 1, day 3 and day 5 
swimming assessment, fewer worms from 
the transgenic strains relative to N2 
appeared to have survived to day 5. In 
essence, although the transgenic worms 
appeared normal up through early 
adulthood, they showed impaired 
locomotion, reduced egg-laying and 





This study was designed and carried out 
with the goal of creating a new model of 
tauopathy.  
4.1 Extra-chromosomal mutant tau 
causes behavioral deficits 
I explored whether a model of tauopathy 
could be made using endogenously-
restricted locations of expression. Worms 
with mutant tau under the endogenous 
promoter showed fewer head bends in 
forward movement, made fewer proper C-
shaped bends while swimming and trended 
toward laying fewer eggs. These worms also 
appeared to have shorter lifespans, though 
this was not quantitatively assessed. Similar 
motor deficits were found with a previous 
tau model using a pan-neuronal promoter. A 
strain with a non-mutant form of tau would 
help to determine if mutant tau is required 
for behavioral defects or overexpression of 
wild-type tau is sufficient. Kraemer et al. 
(2003) created a model expressing wild-type 
tau under a pan-neuronal promoter. 
Although, this model demonstrated 
behavioral deficits, defects were not as 
severe as in the mutant tau models, 
suggesting the mutant form of tau may be 
causing the severity of the observed 
phenotypes. Together these findings and 
previous studies show that both pan-
neuronal and endogenous overexpression of 
mutant tau cause similar deleterious 
behavioral effects. The current model was 
created with the intent to create a single-
copy integrated tau worm model of 
tauopathy. Unlike the previous pan-
neuronally driven P301L tau model, the 
expression of tau-P301L in the current 
model was driven by the promoter for ptl-1, 
resulting in expression in the embryonic 
epidermis and in the mechanosensory 
neurons [16]. Up through adulthood, 
developing worms appeared to move 
normally, which contrasts with the results 
seen in [7] Kraemer et al., 2003, where 
uncoordinated movement was often seen 
after hatching. Since [7] Kraemer et al., 
2003, used a pan-neuronal promoter while 
the current model used a less-broadly 
expressed promoter, this suggests that the 
quantity and/or specific location of tau 
expression may be causing the behavioral 
changes. A single copy insertion of tau will 
help determine whether there is a dose-
dependent effect of tau overexpression.  
In the present study, I created a new 
tauopathy model expressing an 
endogenously-driven mutant form of tau 
(tau-P301L), which demonstrated behavioral 
deficits. Further exploration is needed to 
more accurately and thoroughly characterize 
this model. Additional injections must be 
done to acquire a single-copy integrated 
model of tauopathy to explore whether 
phenotypic differences between this model 
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